Published 19 December 2024 This call consists of prioritized health technology topics under the HTA general track and are proceeding to the following assessments: The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics – Batch 4 Call [FEC topics and Cycle 1 continue reading : CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – Batch 4 (FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments; and, Cycle 2 topics for Clinical Assessments]
CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – Batch 3 (FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments]
Published 19 December 2024 This call consists of prioritized health technology topics that underwent clinical assessment under the HTA general track and are proceeding to the following assessments: The Health Technology Assessment (HTA) Philippines invites interested researchers to submit capsule proposals under the HTA Research Agenda Program: 2024 HTA Topics – Batch 3 Call [FEC continue reading : CALL FOR PROPOSALS: HTA Research Agenda Program [HTA Research Topics 2024 – Batch 3 (FEC topics and Cycle 1 topics for Economic Assessments and Ethical, Legal, Social, and Health Systems Implication (ELSHI) Assessments]
Omnibus HTA Tracker
Date of Last Update: 25 November 2024 HTA Philippines shares with its stakeholders the 🗃️Omnibus HTA Tracker, a comprehensive and up-to-date file that consolidates all completed, and currently being undertaken assessments by the HTA Council and the HTA Division. This serves as a temporary resource while we work on updating the HTA website. The tracker continue reading : Omnibus HTA Tracker
Tocilizumab for treatment of COVID-19 (2021 Assessment)
Return to Latest Recommendation
HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution
Update as of 25 November 2024 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution ended on 22 November 2024 without valid appeals received, this continue reading : HTA Council Preliminary Recommendation on Abacavir/Lamivudine Tablet, Levonorgestrel Intrauterine Delivery (IUD) System, Levonorgestrel Subdermal Implant, Multiple Micronutrient Supplement Capsule, and Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate Powder for Reconstitution